Delta Capital Management LLC Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Mar 25th, 2023

Delta Capital Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,780 shares of the company’s stock after buying an additional 100 shares during the period. Johnson & Johnson makes up approximately 2.3% of Delta Capital Management LLC’s holdings, making the stock its 13th largest holding. Delta Capital Management LLC’s holdings in Johnson & Johnson were worth $3,141,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Glassy Mountain Advisors Inc. purchased a new stake in Johnson & Johnson during the 4th quarter valued at $35,000. TD Capital Management LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at $48,000. Cowa LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at $58,000. Legend Financial Advisors Inc. bought a new position in Johnson & Johnson in the 3rd quarter valued at $59,000. Finally, Piershale Financial Group Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at $61,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.35% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have commented on JNJ. Morgan Stanley upped their price objective on Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 25th. Citigroup upped their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. StockNews.com initiated coverage on Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, Piper Sandler dropped their price target on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $174.73.

Johnson & Johnson Trading Up 1.0 %

Johnson & Johnson stock opened at $152.65 on Friday. The stock has a 50-day moving average of $159.76 and a two-hundred day moving average of $167.52. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. Johnson & Johnson has a one year low of $150.11 and a one year high of $186.69. The stock has a market cap of $397.54 billion, a PE ratio of 22.65, a price-to-earnings-growth ratio of 2.60 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period last year, the business posted $2.13 earnings per share. The firm’s revenue was down 4.4% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.